WHO Director-General Tedros Adhanom Ghebreyesus Says Mpox Is Public Health Emergency Of International Concern
Portfolio Pulse from Benzinga Newsdesk
WHO Director-General Tedros Adhanom Ghebreyesus has declared Mpox a Public Health Emergency of International Concern. This announcement could impact companies involved in vaccine and treatment development for Mpox.
August 14, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aethlon Medical, Inc. (AEMD) could see increased interest due to its involvement in developing treatments for viral diseases, including Mpox.
Aethlon Medical is involved in developing treatments for viral diseases, and the WHO's declaration could lead to increased demand for their products.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Chimerix, Inc. (CMRX) may experience a positive impact as it is involved in antiviral drug development, which could be relevant for Mpox treatment.
Chimerix's focus on antiviral drugs positions it to potentially benefit from increased attention and funding for Mpox treatments.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
GeoVax Labs, Inc. (GOVX) could see a positive impact as it is involved in developing vaccines for infectious diseases, including Mpox.
GeoVax Labs' involvement in vaccine development for infectious diseases makes it a key player in the response to the Mpox emergency.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Inovio Pharmaceuticals, Inc. (INO) may benefit from the WHO's declaration due to its work on DNA-based vaccines, which could be relevant for Mpox.
Inovio's focus on DNA-based vaccines positions it to potentially benefit from increased demand for Mpox vaccines.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Moderna, Inc. (MRNA) could see increased interest due to its expertise in mRNA vaccine technology, which could be applied to Mpox.
Moderna's mRNA vaccine technology could be leveraged to develop a vaccine for Mpox, leading to increased interest and potential funding.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
SIGA Technologies, Inc. (SIGA) may experience a positive impact as it is involved in developing antiviral treatments, which could be relevant for Mpox.
SIGA's focus on antiviral treatments positions it to potentially benefit from increased attention and funding for Mpox treatments.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Tonix Pharmaceuticals Holding Corp. (TNXP) could see a positive impact due to its involvement in developing treatments for infectious diseases, including Mpox.
Tonix Pharmaceuticals' involvement in developing treatments for infectious diseases makes it a key player in the response to the Mpox emergency.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70